NLS Pharmaceutics (NASDAQ: NLSP) stock jumped during intraday trading Thursday after a Swiss biopharmaceutical company announced progress in Parkinson’s disease treatment.
NLS Pharmaceutics has unveiled encouraging preclinical findings for compounds targeting Parkinson’s Disease (PD), specifically addressing the alpha-synuclein A53T mutation. These results, derived from multiple in vitro studies, suggest potential advancements in PD treatment options.
The company’s research, employing the Alpha-Synuclein A53T Parkinson’s Disease Genetic Cell-Based Agonist Neurite Outgrowth Assay by Eurofins, highlighted that various compounds from its non-sulfonamide dual orexin agonist (DOXA) platform positively influenced neurite outgrowth. This parameter is critical for neuronal health and regeneration, potentially paving the way for enhanced PD therapies.
Among the compounds, AEX-23 emerged as a promising Orexin 1 Receptor (OX1R) agonist, promoting positive effects on neurite outgrowth and potentially fostering better neuronal connectivity in PD patients. Additionally, AEX-19 showed neuroprotective potential by influencing neurite growth at low concentrations, while AEX-24 indicated a possible role in enhancing alpha-synuclein degradation.
Alex Zwyer, CEO of NLS, emphasized that these findings provide valuable insights that could pave the way for more effective treatments for PD.
Meanwhile, Eric Konofal, Chief Scientific Officer, highlighted the development of two new compounds, AEX-230 and AEX-231. These compounds target cathepsins involved in neurodegenerative disorders, which could advance the understanding and treatment of PD-related neurodegeneration.
While these findings are promising, further research through in vitro and in vivo preclinical studies is essential to optimize dosing, assess long-term efficacy, and ensure the safety profile of these compounds in clinical settings.
Founded in 2015, Switzerland-based NLS Pharmaceutics collaborates with esteemed partners to develop innovative therapies for rare and complex central nervous system disorders. Aexon Labs, integral to this research, focuses on addressing unmet needs in neurodegenerative disorders.
NLS Pharmaceutics (NASDAQ: NLSP) Stock Price Action
On Thursday, NLSP stock soared 31.43%, closing at $0.24, marking a 28.41% increase for the week. The trading volume was 162,701,392 shares, significantly higher than the average daily volume of 9.36 million.
NASDAQ: NLSP NLS Pharmaceutics NLSP NLSP shares NLSP stock NLSP stock news
